- $12.8 billion: Projected global PDC market value by 2030, with over 100 candidates in development.
- Complete responses: AVA6207 achieved 100% response rates in SLFN11-low ovarian cancer PDX models and 80% in ATM-low/SLFN11-low NSCLC models.
- £12.5 million: Recent equity raise to extend Avacta's cash runway into Q2 2027.
Experts would likely conclude that Avacta's dual-payload PDC approach represents a promising evolution in precision oncology, potentially overcoming key limitations of first-generation ADCs through targeted synthetic lethality.
The Resistance Wall: How Avacta's Dual-Payload Conjugate Aims to Outsmart Cancer's Defenses
LONDON and PHILADELPHIA – November 19, 2026 – In the high-stakes biological arms race between modern medicine and oncology, cancer frequently finds a loophole. For years, the pharmaceutical industry has poured billions into antibody-drug conjugates (ADCs)—molecular guided missiles that deliver toxic payloads directly to tumors. Drugs like Enhertu have revolutionized treatment, yet they all eventually slam into the same clinical barrier: the resistance wall. Tumors adapt, mutate, and learn to survive the very toxins designed to eradicate them.
Today, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Avacta Therapeutics presented preclinical data that may offer a sophisticated detour around this wall. The company unveiled findings on AVA6207, a next-generation peptide-drug conjugate (PDC) that abandons the traditional single-warhead approach. Instead, it delivers a simultaneous, dual-payload strike aimed specifically at dismantling the tumor's ability to repair itself.
As the industry watches the limitations of first-generation ADCs materialize in the clinic, this approach highlights a critical evolution in precision oncology: moving beyond simply finding the tumor, to fundamentally short-circuiting its survival mechanisms.
Beyond the Antibody: The Peptide Advantage
To understand the significance of AVA6207, one must first understand the limitations of the current standard. Traditional ADCs rely on bulky antibodies to navigate the bloodstream and bind to cancer cells. While effective, their large size can hinder deep tumor penetration, and their circulation time often leads to systemic toxicity as the payload prematurely leaks into healthy tissue.
Avacta’s pre|CISION platform takes a different route, utilizing a peptide backbone rather than an antibody. Peptide-drug conjugates are significantly smaller, allowing for rapid tissue penetration. The global PDC market is projected to exceed $12.8 billion by 2030, with over 100 candidates currently in active development. But AVA6207’s true differentiator lies in its trigger and its payload.
The compound utilizes fibroblast activation protein (FAP)—an enzyme heavily overexpressed in the tumor microenvironment but largely absent in healthy tissue—as a molecular scissor. When the PDC encounters FAP, it cleaves, releasing not one, but two distinct drugs: exatecan and berzosertib.
Exatecan is a potent topoisomerase 1 inhibitor (TOP1i), the same class of DNA-damaging agent that powers blockbuster ADCs. Berzosertib is an ATR inhibitor, a drug designed to block the DNA damage response (DDR) pathway. By delivering both simultaneously, the therapy inflicts severe DNA damage and immediately paralyzes the cancer cell's ability to repair it. It is a highly engineered biological trap, ensuring that tumors resistant to standard TOP1i therapy are forced into fatal mitotic catastrophe.
Exploiting Genetic Vulnerabilities
The science of dual-payload delivery is complex, but the clinical strategy relies on a concept known as synthetic lethality. The developers are not proposing a blanket treatment for all cancers; rather, they are targeting specific genetic vulnerabilities—namely, tumors exhibiting a loss of Schlafen family member 11 (SLFN11) or a deficiency in the ataxia telangiectasia mutated (ATM) kinase.
Both SLFN11 loss and ATM deficiency leave cancer cells uniquely dependent on the ATR kinase for survival. By pre-selecting patients with these specific biomarker profiles, the goal is to maximize therapeutic efficacy.
The preclinical data presented in Barcelona underscores the potential of this targeted approach. In patient-derived xenograft (PDX) models, AVA6207 achieved complete responses in all tested models of SLFN11-low ovarian cancer, and in four out of five ATM-low and SLFN11-low non-small cell lung cancer (NSCLC) models. Furthermore, in a gastric cancer PDX model, the compound demonstrated superiority over Enhertu, suggesting a tangible efficacy advantage in specific resistant settings.
"What is striking about the data presented is that AVA6207 goes beyond simply restoring sensitivity in these resistant tumors," said Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta. "The complete responses observed in SLFN11-low and ATM-low PDX models, taken together with the remarkable consistency across the datasets for all our pre|CISION medicines including AVA6103 and AVA6000, give the Board increasing confidence as we move the dual payload program towards clinical development."
From a clinical feasibility standpoint, this biomarker-driven strategy is highly pragmatic. Next-generation sequencing (NGS) to detect ATM mutations is already a standard practice for guiding treatment in certain cancers, such as pancreatic ductal adenocarcinoma and NSCLC. While diagnostic standardization for SLFN11 is still maturing, the trajectory of precision oncology clearly favors therapies that can identify their ideal responders before the first dose is ever administered.
The Economics of Precision
However, compelling science does not exist in a vacuum; it is inextricably linked to the economic realities of biotechnology. Advancing a novel asset from candidate selection into human trials requires immense capital.
The company has confirmed that AVA6207 will move into Investigational New Drug (IND)-enabling studies in the fourth quarter of 2026. To fuel this transition, Avacta recently undertook a £12.5 million equity capital raise. This financial maneuver was critical, extending its cash runway from early Q1 2027 into Q2 2027, buying vital time to hit clinical milestones and, crucially, to negotiate at the partnering table.
In the current biotech landscape, strategic partnerships are the lifeblood of mid-stage companies. While existing collaborations with entities like Tempus AI and LG Chem are foundational, advancing a complex dual-payload PDC through late-stage trials will likely require the deep pockets and global infrastructure of a major pharmaceutical partner.
Coughlin alluded to this dynamic, noting that the consistency of their datasets "enables our multiple different levers to generate the capital investment needed to move these exciting programs forward in the clinic." The Barcelona data is not just a scientific validation; it is a meticulously crafted pitch to potential partners seeking to replenish their oncology pipelines with next-generation conjugate technologies.
A New Chapter in Oncology
The pursuit of dual-payload conjugates represents a fundamental shift in how the pharmaceutical industry approaches tumor eradication. For decades, the strategy was akin to a blunt instrument—deploying maximum toxicity and hoping the cancer died before the patient's healthy tissues did. The advent of ADCs refined this into a targeted strike, but the emergence of resistance has proven that cancer is too dynamic for a single mechanism of action.
AVA6207 embodies the next logical step: a molecular Trojan horse that uses the tumor's own microenvironment to trigger a coordinated, multi-pronged attack. By simultaneously inflicting DNA damage and disabling the repair crew, all within the confines of a tumor-specific peptide delivery system, the therapy addresses the root causes of drug resistance.
As the asset progresses toward IND-enabling studies, it carries the weight of a broader industry question. The coming years will determine whether peptide-drug conjugates can truly outmaneuver their antibody predecessors, and whether a dual-payload strategy can finally breach the resistance wall that has long constrained the potential of targeted cancer therapies.
Topics & Related
Clinical & Scientific
Precision Medicine
Biotechnology
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →